- Home
- CTO vs EYPT Comparison
CTO vs EYPT Comparison
Compare CTO & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTO
- EYPT
- Stock Information
- Founded
- CTO 1902
- EYPT 1987
- Country
- CTO United States
- EYPT United States
- Employees
- CTO N/A
- EYPT N/A
- Industry
- CTO Real Estate Investment Trusts
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- CTO Real Estate
- EYPT Industrials
- Exchange
- CTO Nasdaq
- EYPT Nasdaq
- Market Cap
- CTO 578.8M
- EYPT 594.5M
- IPO Year
- CTO N/A
- EYPT 2005
- Fundamental
- Price
- CTO $19.43
- EYPT $7.20
- Analyst Decision
- CTO Strong Buy
- EYPT Strong Buy
- Analyst Count
- CTO 4
- EYPT 8
- Target Price
- CTO $21.50
- EYPT $25.71
- AVG Volume (30 Days)
- CTO 448.8K
- EYPT 868.2K
- Earning Date
- CTO 02-20-2025
- EYPT 03-06-2025
- Dividend Yield
- CTO 7.81%
- EYPT N/A
- EPS Growth
- CTO N/A
- EYPT N/A
- EPS
- CTO 0.61
- EYPT N/A
- Revenue
- CTO $118,662,000.00
- EYPT $45,713,000.00
- Revenue This Year
- CTO N/A
- EYPT N/A
- Revenue Next Year
- CTO $13.12
- EYPT N/A
- P/E Ratio
- CTO $32.08
- EYPT N/A
- Revenue Growth
- CTO 16.61
- EYPT 7.50
- 52 Week Low
- CTO $16.16
- EYPT $6.90
- 52 Week High
- CTO $21.15
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- CTO 45.84
- EYPT 40.40
- Support Level
- CTO $18.89
- EYPT $6.91
- Resistance Level
- CTO $19.74
- EYPT $9.50
- Average True Range (ATR)
- CTO 0.37
- EYPT 0.62
- MACD
- CTO -0.02
- EYPT 0.07
- Stochastic Oscillator
- CTO 52.94
- EYPT 11.20
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a Florida-based real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.